| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02512679 Details | 2017-02-27 Interventional | 2 | [1 Refs] | 20 | Cyclophosphamid… Anemia, Diamond… Genetic Disease… Granulomatous D… Immunologic Def… Lymphoprolifera… Metabolic Disea… Thalassemia Wiskott-Aldrich… Allogeneic Tran… Bone Marrow Tra… Chronic Granulo… Combined Immune… Diamond-Blackfa… Genetic Disease… Pediatrics Peripheral Bloo… Stem Cell Trans… X-linked Lympho… | Optimal dose obtained for engraftment and minimizing toxicity De-escalation was not ensued. All enrolled subjects engrafted without toxicity for dose level one. | ||
| NCT01989091 Details | 2017-02-27 Interventional | 3 | 270 | Heparin Dialysis Cathet… | Did not meet predetermined primary endpoint - | |||
| NCT01601704 Details | 2017-02-27 Interventional | 3 | 8910 | Bupropion hydro… Overweight Obesity | - The study was terminated early. Outcome measures data is based on the 50% interim analysis, designated as the primary analysis. Safety data is based on all available data at the time of database lock, which occurred after the 50% interim analysis. | |||
| NCT01967199 Details | 2017-02-24 Interventional | 4 | 175 | Everolimus Paclitaxel Coronary Resten… | - - | |||
| NCT01899690 Details | 2017-02-24 Interventional | 4 | 0 | Anti-Bacterial … Cephalexin Clindamycin Communicable Di… Infections Inflammation Complications; … | The study was withdrawn prior to IRB approval. - | |||
| NCT00171938 Details | 2017-02-24 Interventional | 2 | 30 | Imatinib Mesyla… Glioblastoma | - - | |||
| NCT01493505 Details | 2017-02-23 Interventional | 3 | 1015 | Carboplatin Paclitaxel Trebananib Carcinoma, Ovar… Fallopian Tube … Ovarian Neoplas… Fallopian Tube … Ovarian Cancer Peritoneal Canc… | Amgen Administrative Decision - termination of LTFU - | |||
| NCT00841945 Details | 2017-02-23 Interventional | 3 | 334 | Doxorubicin Prednisone Rituximab Vincristine Lymphoma B Cell Lymphoma | other drugs other studies - | |||
| NCT00637780 Details | 2017-02-23 Interventional | 4 | 2 | Sulfasalazine Arthritis Arthritis, Juve… Arthritis, Juve… | Study terminated on 13 April 2016 for business reasons. No safety and/or efficacy concerns
contributed to the termination of the study The study was terminated prematurely and only 2 participants were enrolled and completed the study. | |||
| NCT00470535 Details | 2017-02-23 Interventional | 2 | 18 | Erlotinib Hydro… Pancreatic Neop… Pancreatic Canc… | This study was terminated earlier due to a phase III study that showed this drug inferior to
sorafenib This study was terminated earlier due to a phase III study that showed this drug was not better than sorafenib | |||
| NCT00240981 Details | 2017-02-23 Interventional | 4 | [1 Refs] | 209 | Testosterone Hypogonadism Muscular Diseas… Sarcopenia | Higher incidence of cardiovascular events in the testosterone arm of the trial. Decision taken
by the DSMB on December 31st, 2009. - | ||
| NCT02723981 Details | 2017-02-20 Interventional | 4 | 0 | Anticoagulants Clopidogrel Dabigatran Rivaroxaban Vitamin K Vitamins Angina Pectoris Angina, Stable Angina, Unstabl… Coronary Diseas… NSTEMI STEMI Stable Angina Unstable Angina | Regulatory authority approval for the initial study design could not be obtained - | |||
| NCT01621477 Details | 2017-02-20 Interventional | 2 | 34 | Antilymphocyte … Busulfan Clofarabine Cyclophosphamid… Cytarabine Mycophenolic Ac… Plerixafor Tacrolimus Thymoglobulin Hematologic Neo… Leukemia Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Myelodysplastic… Neoplasms Precursor Cell … Sarcoma, Myeloi… Acute Lymphobla… Acute Myelocyti… Chronic Myelocy… Hodgkin or Non-… Juvenile Myelom… Myelodysplastic… | Study was terminated in August 2016 due to replacement by a new study. - | |||
| NCT01574248 Details | 2017-02-17 Interventional | 4 | 33 | Icatibant Angioedema ACE Inhibitor-a… | DSMC recommended discontinuation for futility and feasibility - | |||
| NCT01338857 Details | 2017-02-17 Interventional | 2 | 12 | Sorafenib Astrocytoma Glioma Neurofibroma Neurofibromatos… Neurofibromatos… Recurrence Recurrent or Pr… Recurrent or Pr… neurofibromatos… | Sorafenib ineffective for tx of recurrent or progressive PLGA - | |||
| NCT01179594 2009-017602-36 Details | 2017-02-17 Interventional | 4 | 0 | Entecavir Interferon-alph… Peginterferon a… Hepatitis Hepatitis A Hepatitis B Hepatitis B, Ch… | This study was canceled for operational reasons. - | |||
| NCT00250692 Details | 2017-02-17 Interventional | 3 | 0 | Nitrous Oxide Analgesic Affec… | unknown - no record of study conduct in departmental archive - | |||
| NCT02254551 Details | 2017-02-16 Interventional | 2 | 7 | Bortezomib Multiple Myelom… Neoplasms, Plas… | Safety lead-in data did not support continuation of study. Early termination of study during dose-escalation did not support continuation of study. | |||
| NCT02716090 Details | 2017-02-15 Interventional | 3 | 0 | Adapalene Benzoyl Peroxid… Acne Vulgaris | Due to budget limitations, the company decided to withdraw this study. - | |||
| NCT01838642 Details | 2017-02-15 Interventional | 2 | 3 | Ponatinib Thyroid Disease… Thyroid Neoplas… | Recruiting halted prematurely and will not resume. New study to open soon. - |